TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $152.3333.

A number of equities research analysts have issued reports on the stock. TD Cowen reiterated a “buy” rating on shares of TransMedics Group in a report on Monday. Canaccord Genuity Group boosted their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC upped their price objective on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Stifel Nicolaus raised their price target on TransMedics Group from $115.00 to $130.00 and gave the stock a “hold” rating in a report on Monday, March 9th.

Insiders Place Their Bets

In related news, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the completion of the transaction, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at $2,162,367.69. This represents a 33.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 864 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the transaction, the insider owned 13,091 shares in the company, valued at $1,821,219.92. The trade was a 6.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. D.A. Davidson & CO. grew its holdings in shares of TransMedics Group by 0.5% during the fourth quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after buying an additional 83 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after buying an additional 83 shares during the period. HighPoint Advisor Group LLC increased its stake in TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after acquiring an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after purchasing an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of TransMedics Group by 2.9% in the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Down 9.2%

Shares of NASDAQ TMDX opened at $113.21 on Thursday. The business’s 50 day moving average is $135.25 and its two-hundred day moving average is $127.36. TransMedics Group has a 52-week low of $62.23 and a 52-week high of $156.00. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 23.10 and a beta of 1.98. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.